Sunshine Lake Pharma Co., Ltd.
The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants with type 2 diabetes (T2D).
Diabetes
Insulin Degludec and Insulin Aspart
PHASE3
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 408 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Multi-center, Randomized, Open, Phase III Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared Efficacy and Safety With Insulin Degludec/Insulin Aspart(Ryzodeg) in Chinese Subjects With Type 2 Diabetes |
Actual Study Start Date : | 2023-05-01 |
Estimated Primary Completion Date : | 2023-12-01 |
Estimated Study Completion Date : | 2024-03-01 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
No Location Found